Cargando…

Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization

Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML). The R345W F3 mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodard, DaNae R., Nakahara, Emi, Hulleman, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862258/
https://www.ncbi.nlm.nih.gov/pubmed/33542268
http://dx.doi.org/10.1038/s41598-020-79570-x
_version_ 1783647250399887360
author Woodard, DaNae R.
Nakahara, Emi
Hulleman, John D.
author_facet Woodard, DaNae R.
Nakahara, Emi
Hulleman, John D.
author_sort Woodard, DaNae R.
collection PubMed
description Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML). The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells. Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity. Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels). Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue. To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants. This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels). Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F). These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
format Online
Article
Text
id pubmed-7862258
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78622582021-02-05 Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization Woodard, DaNae R. Nakahara, Emi Hulleman, John D. Sci Rep Article Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML). The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells. Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity. Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels). Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue. To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants. This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels). Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F). These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism. Nature Publishing Group UK 2021-02-04 /pmc/articles/PMC7862258/ /pubmed/33542268 http://dx.doi.org/10.1038/s41598-020-79570-x Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Woodard, DaNae R.
Nakahara, Emi
Hulleman, John D.
Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization
title Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization
title_full Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization
title_fullStr Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization
title_full_unstemmed Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization
title_short Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization
title_sort clinically-identified c-terminal mutations in fibulin-3 are prone to misfolding and destabilization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862258/
https://www.ncbi.nlm.nih.gov/pubmed/33542268
http://dx.doi.org/10.1038/s41598-020-79570-x
work_keys_str_mv AT woodarddanaer clinicallyidentifiedcterminalmutationsinfibulin3arepronetomisfoldinganddestabilization
AT nakaharaemi clinicallyidentifiedcterminalmutationsinfibulin3arepronetomisfoldinganddestabilization
AT hullemanjohnd clinicallyidentifiedcterminalmutationsinfibulin3arepronetomisfoldinganddestabilization